Background: Human papillomavirus (HPV) is a leading cause of cervical cancer and other HPV-related cancers globally. Vaccination against HPV has proven to be a pivotal intervention in reducing the burden of these diseases. However, questions remain regarding long-term efficacy, dosing strategies, and real-world outcomes of HPV vaccines. Objective: We aim to synthesise evidence from randomised controlled trials and long-term follow-up studies on the efficacy, immunogenicity, safety, and real-world impact of HPV vaccines. Methodology: A comprehensive search was conducted in PubMed, Cochrane Library, Embase, Scopus, and Web of Science for studies published in English from 2019 to 2024. Eligible studies included randomised controlled trials and long-term follow-up analyses focusing on HPV vaccine efficacy, dosing regimens, and population-specific outcomes. Data were extracted and synthesised narratively, with findings organised into five thematic areas. Results: Seventeen studies met the inclusion criteria. Findings confirm the high efficacy of HPV vaccines in preventing HPV-related cancers and precancers, with durable immunogenicity observed up to 12 years post-vaccination. Evidence supports the potential of single-dose regimens, which could improve accessibility in resource-limited settings. Real-world data demonstrated significant reductions in HPV-related diseases across diverse populations, reinforcing the global impact of HPV vaccination programs. Conclusion: This review highlights the critical role of HPV vaccines in reducing the burden of HPV-related cancers, with robust efficacy, long-term protection, and favourable safety profiles. The findings underscore the need for continued research into optimised vaccination strategies and the expansion of global vaccination efforts.
HPV vaccinationhuman papillomaviruscervical cancer preventionHPV-associated cancers
Annals of Medicine · مجلد 57 (1) · 2516697-2516697
INTRODUCTION: Several severe disorders, such as inherited diseases (e.g. cystic fibrosis and beta thalassemia), genetic diseases (e.g. malignant tumors and diabetes), and infectious diseases (e.g. HIV) are pose significant challenges to human health. BACKGROUND: Over the past few decades, researchers have been working on gene therapies, and currently, terrible dreams have come true. To date, the Food and Drug Administration (FDA) has approved multiple gene therapies such as Kynamro for familial hypercholesterolaemia, Exondys51 for duchenne muscular dystrophy, Spinraza for spinal muscular atrophy, etc., rest for cancer, infectious diseases, and rare diseases. DISCUSSION: The authors have summarized recent advances in gene therapy, its background, molecular basis (e.g. viral and non-viral vectors), gene-editing techniques (e.g. CRISPR/Cas9, TALEN, ZFN), and its foremost applications in severe disorders, such as cancer, monogenic disorders (e.g. spinal muscular atrophy), polygenic disorders (e.g. autism), neurogenic disorders (e.g. Parkinson disease and Alzheimer's disease), and infectious diseases (e.g. HIV). CHALLENGES: In addition, we explored the major challenges faced by gene therapies during targeted delivery, immunogenicity, efficacy, and safety. CONCLUSION: have paved the foundation for applications of gene therapies. Additionally, advances in enhancing the immune system that would certainly lower the healthcare costs. This review highlights the translatory potential of gene therapy in revolutionizing the treatment landscape for severe disorders.
Immunity Inflammation and Disease · مجلد 13 (9) · e70253-e70253
OBJECTIVES: The current systematic review and meta-analysis aims to assess the safety and immunogenicity of the anticaries vaccines currently available. MATERIALS AND METHODS: Electronic searches of PubMed, Scopus, Web of Science and Science Direct were performed. Studies assessing the safety and effectiveness of the anticaries vaccination, including the dose, plasmids, serum IgG and IgA levels after immunization, were included. Studies in which animals were used for anticaries vaccine were also included. Combining more than one trial was done to estimate the pooled intervention effect using the meta-analysis when studies examined the same intervention and outcomes with comparable methods in similar populations. The continuous data was pooled using the inverse variance method, and dichotomous data using the Mantel-Haenszel method. RESULTS: Out of 4701 records, only 17 publications met the eligibility criteria. Although all studies were assessed as having an overall low risk of bias, certain domains (D3, D5, and D7) exhibited a high risk across most studies. The pooled RR, derived using a random-effects model, was 0.53 (95% CI: 0.46-0.62), indicating a statistically significant 47% reduction in risk across studies. CONCLUSIONS: There is excellent potential for dental caries vaccines to transform oral health in the future. Various vaccines, such as Killed Formalin-treated Donor strain 2 - recombinant Protein Antigen c and anti-CAT-SYIIgY antibodies, have demonstrated prophylactic effects against Streptococcus mutans colonization on teeth. These interventions exhibit a sustained reduction in S. mutans colonization, which may contribute to the prevention of dental caries. A vaccination of this kind would significantly lower tooth decay prevalence and the financial and health costs that go along with it.
Advanced Health Science and Technology Journal · مجلد 1 (1) · 9-22
Abstract Neurodegenerative diseases (NDDs) pose a significant global health challenge, causing progressive neuronal loss and debilitating impairments. While current treatments offer only symptomatic relief, small interfering RNAs (siRNAs) have emerged as a promising therapeutic modality. This systematic review analyzed the literature (2000-2025) from different databases on siRNA therapy for NDDs, focusing on mechanisms, delivery approaches, therapeutic efficacy, and safety profiles to provide an integrated, evidence-based synthesis. The siRNA precise sequence specificity allows them to silence disease-related genes, addressing the root causes of these disorders. This review examines the fundamental biology of siRNAs, including advancements in their design, chemical modification, and innovative strategies to overcome the blood–brain barrier (BBB) for central nervous system delivery. We detail siRNA-based therapeutic strategies for major NDDs – Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis – highlighting the transition from preclinical successes to clinical trials. Despite challenges in delivery and immunogenicity, the precision of siRNA-mediated gene silencing positions this technology at the forefront of efforts to develop disease-modifying treatments, paving the way for a new era of personalized neurotherapeutics.
BACKGROUND: Bacterial ghosts are the evacuated bacterial cellular membranes from most of the genetic and protein contents which preserved their surface characters. Recently, bacterial ghosts exploited for different biomedical applications, for instance, vaccination. The purpose of this study is to measure the immunogenic protective response of bacterial ghosts of Salmonella Typhimurium in animals and to allow future testing this response in humans. The immunologic response was qualitatively, quantitatively, and functionally measured. We have measured the humoral and cellular immune responses, such as immunoglobulins elevation (IgG), increased granulocytes, serum antibacterial activity, clearance of virulence in feces and liver, and the survival rate. RESULTS: The bacterial ghosts' vaccine was able to protect 100% of subcutaneously vaccinated rats and 75% of adjuvant subcutaneously vaccinated rats. The lowest survival rate was in the orally vaccinated group (25%). The maximum level of serum IgG titers, as well as serum and feces bactericidal activity (100% eradication), was exhibited in the subcutaneously vaccinated group with adjuvant vaccines followed by the subcutaneously vaccinated one. Additionally, the highest granulocytes' number was observed in the adjuvant vaccine subcutaneously immunized group. The bacterial load in liver homogenate was eliminated in the subcutaneously vaccinated rats after the virulence challenge. CONCLUSIONS: The bacterial ghosts of Salmonella enterica serovar Typhimurium that prepared by Tween 80 Protocol showed an effective vaccine candidate that protected animals, eliminated the virulence in feces and liver. These findings show that chemically induced bacterial ghosts of Salmonella Typhimurium can be a promising vaccine.